Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Runyon

Anesthesiology Durham, NC Medical Doctor

NPI 1831356377 CMS profile 870759

2100 Erwin Rd, Durham, NC 27705

Open in the dashboard

General payments

$123,229

137 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Runyon of Durham, NC is reported in the CMS Open Payments database as having received $123,229 across 137 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $238 4
2023 General $11 1
2022 General $3,602 10
2021 General $26,119 31
2020 General $26,184 22
2019 General $67,073 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Runyon
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Scott Runyon were reported at $238. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Scott Runyon Anesthesiology median Middle half National median
2019 $67,073 $72 $23–$151 $163
2020 $26,184 $36 $17–$120 $114
2021 $26,119 $49 $21–$135 $132
2022 $3,602 $52 $22–$144 $149
2023 $11 $53 $23–$143 $160
2024 $0 $55 $25–$150 $164
2025 $238 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $103,139 104 payments
  2. Abbott Laboratories $19,975 28 payments
  3. GRT US Holding, Inc. $58 1 payment
  4. Medtronic USA, Inc. $30 2 payments
  5. Vertex Pharmaceuticals Incorporated $16 1 payment
  6. MML US, Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $89,418 31 payments
  2. Consulting Fee $21,600 18 payments
  3. Travel and Lodging $8,224 31 payments
  4. Food and Beverage $3,987 57 payments
Products named General payments · program years 2019–2025
  1. SPECTRA WAVEWRITER $67,226 41 payments
  2. Proclaim Family of SCS IPGs $18,437 25 payments
  3. WAVEWRITER ALPHA $18,161 5 payments
  4. GENERAL PAIN MANAGEMENT Pain Management $5,919 16 payments
  5. WaveWriter Alpha Prime 16 $3,460 8 payments
  6. GENERAL - PAIN MANAGEMENT $2,095 4 payments
  7. GENERAL THERAPIES $1,800 8 payments
  8. Neuromodulation Dspsbls and Accs $1,513 2 payments
  9. General Pain Management General $1,109 5 payments
  10. General - Therapies $830 1 payment
  11. Other $2,679 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,097

Median for Anesthesiology: 322

Drug cost

$76,103

Median for Anesthesiology: $8,738

Branded share of claims

23.4%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Botox Onabotulinumtoxina Brand 12 $15,300
Oxycodone Hcl Generic 473 $12,115
Xtampza Er Oxycodone Myristate Brand 15 $9,289
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 183 $6,101
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 160 $6,097
Tramadol Hcl Er Tramadol Hcl Brand 47 $3,917
Gabapentin Generic 212 $3,731
Pregabalin Generic 146 $3,256
Celecoxib Generic 80 $2,886
Baclofen Generic 61 $2,791

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$85,924

Medicare's payments for the services billed

Medicare patients

200

Average age 73

Services billed

1,104

111 women, 89 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Chronic kidney disease 34%
Depression 33%
Diabetes 30%
Ischemic heart disease 25%
Osteoporosis 25%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

137 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record